Yifan Pharmaceutical's subsidiary gets clinical trial approval

Yifan Pharmaceutical (SZSE:002019) announced that its wholly-owned subsidiary, Yifan Pharmaceutical (Shanghai) Co., Ltd., has received a "Drug Clinical Trial Approval Notice" from the National Medical Products Administration for its Human Somatropin Injection. The drug, a biosimilar to Novo Nordisk's Norditropin, is intended for treating growth hormone deficiency in children and adults, mirroring Norditropin's current indications in China. The company states that the project is in its early stages and will not significantly impact its short-term performance. It cautions investors about potential risks, including evolving regulatory standards and possible supply chain disruptions. Yifan Pharmaceutical plans to disclose further developments in compliance with regulations.